Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: A disease or a drug effect?

Ron Ram, Anat Gafter-Gvili, Elimelech Okon, Idit Pazgal, Ofer Shpilberg, Pia Raanani

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Gelatinous marrow transformation (GMT) is an unusual pathological manifestation of progressive malignant diseases and severe malnutrition states. GMT has been associated with various accelerated hematological malignancies, but has never been described in patients with chronic myelogenous leukemia (CML) treated with imatinib mesylate (IM), a novel tyrosine kinase inhibitor. Herein we report 2 patients with stable chronic phase CML who developed GMT during the course of treatment with IM. A comprehensive review of the relevant published data, several possible mechanisms and therapeutic alternatives are suggested.

Original languageEnglish
Pages (from-to)104-107
Number of pages4
JournalActa Haematologica
Volume119
Issue number2
DOIs
StatePublished - 1 Apr 2008
Externally publishedYes

Keywords

  • Chronic myeloid leukemia
  • Gelatinous transformation
  • Imatinib

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: A disease or a drug effect?'. Together they form a unique fingerprint.

Cite this